November 10, 2017

FIMM and Labcyte expand collaboration

In FIMM's innovative approach to cancer care, hundreds of drug options are tested on the patient's cancer cells in the lab to help tailor treatment plans.
In FIMM's innovative approach to cancer care, hundreds of drug options are tested on the patient's cancer cells in the lab to help tailor treatment plans.
Screenshot / FIMM

The Institute for Molecular Medicine Finland (FIMM) has extended its collaboration with biotechnology tools company Labcyte, with multiple new approaches to personalised medicine that leverage Labcyte’s acoustic liquid handling technology.

FIMM, a unit of the Helsinki Institute of Life Science at the University of Helsinki, started collaborating with Labcyte in 2013 to develop new personalised medicine strategies for cancer treatment based on functional cell screening.

The collaboration enabled scientist at FIMM to develop an innovative approach to cancer care, where the effects of hundreds of different drug options are tested on the patient’s cancer cells in the lab using Labcyte’s acoustic liquid handling technology. The results are then combined with the patient’s DNA data to create a tailored treatment plan.

The two have now expanded the collaboration with cell-based assay development and screening, such as lysate-based assays for multiplexing and standard miniaturised assays, while also integrating Labcyte’s Echo liquid handler in FIMM’s genomics program to include single cell genomics and population genetics workflows.

“The collaboration with FIMM has been one of our most successful and productive to date,” says Mark Fischer-Colbrie, CEO at Labcyte. “We have been working together for the past four years to break new ground in personalised medicine and functional cell screening, and this work is being modeled now in many centers around the world. The team at FIMM have enabled patients to achieve remission and identified drugs and drug combinations that can be used more broadly.”

Share: